Medicare Opioid Abuse Prevention Measures To Be Enhanced In 2019
Executive Summary
Part D plans would need expanded point-of-sale 'edits' for high-dose prescriptions and supply limits for patients new to opioids under proposal in 2019 'call letter' for the Medicare pharmacy benefit.
You may also be interested in...
US FDA Learns 'Lessons Of History,' Takes Opioid Fight To Gabapentinoids
Agency investigating potential misuse and abuse of gabapentinoids, which CDC had recommended as alternative to opioids, in latest twist to epidemic.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.